Patients with marker-negative clinical stage IIA/B seminoma or nonseminoma represent a therapeutic challenge, as 20-30% might harbor nonmalignant histologies. MicroRNA 371a-3p (miR371) may represent a biomarker with diagnostic and predictive properties in testicular germ cell tumors (TGCTs). We evaluated the predictive accuracy of this biomarker in identifying the presence or absence of lymph node metastases (LNMs) in clinical stage IIA/B TGCT. In a cohort of 24 consecutive patients with marker-negative clinical stage IIA/B TGCT (n = 15 seminoma, n = 9 nonseminoma) serum miR371 was assessed 1 d before nerve-sparing retroperitoneal lymphadenectomy. Histology revealed metastatic TGCT in 22/24 patients (91.7%), with positive miR371a findings for 20 of these 22 patients with metastases (90.9%). Histology revealed no malignancy in one patient and lymphoma in another, both of whom had negative miR371a findings. One additional patient with pure teratoma and one with a microscopic seminomatous LNM had false-negative miR371a findings. The miR371 assay had sensitivity of 90.9% and specificity of 50%. The positive predictive value was 100.0% and the negative predictive value was 75.0%. According to the data available, miR371a represents a highly reliable, personalized tumor marker for predicting the presence of low-volume retroperitoneal LNMs in marker-negative TGCT. miR371 has potential for inclusion in the diagnostic armamentarium for men with equivocal lymph nodes to facilitate avoidance of unnecessary treatment and the associated toxicity. PATIENT SUMMARY: Our study demonstrates that blood tests for the biomarker miR371 are highly reliable in predicting the presence of lymph node metastases in patients with stage IIA/B testicular cancer. For patients with equivocal findings, use of this test may help in avoiding unnecessary treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.euo.2023.10.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical outcomes of stage IIA/IIB seminoma treated with radiotherapy and chemotherapy: should regional therapy be considered the preferred treatment approach?
Int J Radiat Oncol Biol Phys
January 2025
Radiation Medicine Department, Princess Margaret Cancer Centre, University Health Network; Department of Radiation Oncology, University of Toronto.
Purpose: The optimal management of patients with de novo clinical stage IIA/B (CSIIA/B) or relapsed CSIIA/B (Rel-CSIIA/B) seminoma remains debated due to a lack of randomized evidence. Herein, we sought to evaluate outcomes following radiotherapy and chemotherapy in this setting.
Materials And Methods: A prospectively maintained single-institutional database was retrospectively queried for patients diagnosed between 1995-2016 with de novo or Rel-CSIIA/B.
Impact of multidisciplinary team discrepancies on comparative lung cancer outcome analyses and treatment equality.
BMC Cancer
November 2024
Department of Thoracic Surgery, Rigshospitalet, Copenhagen, DK-2100, Denmark.
Introduction: This study aimed to evaluate the consistency of lung cancer case assessments across multidisciplinary team (MDT) sites in Denmark. The goal was to appraise the comparability of outcomes between hospitals in a real-world context.
Methods: We prepared sixty comprehensive, fictitious lung cancer case stories, complete with images, and distributed them to the four primary lung cancer MDT conferences in Denmark.
Dural arteriovenous fistula may be occluded through recanalization of impaired venous sinuses.
Medicine (Baltimore)
October 2024
Stroke Center, Cerebrovascular Disease Hospital, Henan Provincial People's Hospital, Zhengzhou, Henan Province, China.
To investigate the effect and safety of recanalization of stenosed or occluded venous sinuses for dural arteriovenous fistulas (DAVFs) and possible mechanism of DAVF formation, patients with DAVF accompanied by venous sinus stenosis or occlusion treated with balloon angioplasty and/or stenting were retrospectively enrolled. The clinical data, treatment outcomes and complications were analyzed. In 7 patients enrolled, the DAVF was Cognard IIa grade in 3 (42.
View Article and Find Full Text PDFPrimary retroperitoneal lymph node dissection in stage II testicular seminoma: a systematic review.
BJU Int
February 2025
EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, Australia.
Article Synopsis
- The study aimed to systematically review the role of primary retroperitoneal lymph node dissection (RPLND) in stage II testicular seminoma, analyzing its oncological, functional, and peri-operative outcomes based on existing literature up to November 2023.
- Six studies encompassing 385 patients were reviewed, revealing a median operation time of 187 minutes, a median blood loss of 150 mL, and a typical hospital stay of 4 days, with a complication rate of 6.1% for serious issues.
- While long-term survival data is limited, one study showed a 92% 5-year overall survival for treated stage IIA/B disease, indicating that R
[Primary retroperitoneal lymph node dissection in testicular germ cell cancer in clinical stage IIA/B-renaissance of an established treatment?].
Urologie
November 2024
Klinik für Urologie, Uro-Onkologie, roboter-assistierte und spezielle urologische Chirurgie, Uniklinik Köln, Kerpener Str. 62, 50927, Köln, Deutschland.
Background: The guideline-recommended treatment of choice for clinical stage IIA/B testicular germ cell tumors is chemotherapy with three cycles of PEB/four cycles of PE or, alternatively, radiation for seminomas. Despite their high curative efficacy, both options are associated with significant long-term toxicities. We evaluated the functional and oncological outcomes of primary retroperitoneal lymph node dissection (RPLND) as a therapeutic alternative.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!